Lithium – therapeutic tool endowed with multiple beneficiary effects caused by multiple mechanisms


Share / Export Citation / Email / Print / Text size:

Acta Neurobiologiae Experimentalis

Nencki Institute of Experimental Biology

Polish Neuroscience Society

Subject: Behavioral Sciences , Biomedical Sciences & Nutrition , Life Sciences , Medicine , Neurosciences


ISSN: 0065-1400
eISSN: 1689-0035





Volume / Issue / page

Related articles

VOLUME 76 , ISSUE 1 (March 2016) > List of articles

Advertisement Lithium – therapeutic tool endowed with multiple beneficiary effects caused by multiple mechanisms

Miroslava Vosahlikova * / Petr Svoboda

Keywords : bipolar disorder, lithium, sodium, magnesium, G protein coupled receptors, Na+-allosteric site.

Citation Information : Acta Neurobiologiae Experimentalis. Volume 76, Issue 1, Pages 1-19, DOI:

License : (CC BY 4.0)

Received Date : 10-November-2015 / Accepted: 12-February-2016 / Published Online: 25-July-2017



Mood disorders are relatively common serious human diseases for which there is often no ideal pharmacotherapy. Basic characteristic of these diseases is affective disorder shifting the mood of the patient to depression (together with anxiety or not) or towards to euphoria. Available drugs are usually divided into two groups – mood stabilizers, which are used primarily to treat bipolar disorder,and antidepressants for the treatment of unipolar depression. Lithium is still recommended as the first choice for dealing with bipolar disorder. Despite abundant clinical use of mood stabilizing drugs, important questions regarding their mechanism of action remain open.In this paper we present the brief review of rather diversified hypotheses and ideas about mechanisms of genesis of mood disorders and lithium interferences with these pathological states. New data derived from the high-resolution crystallographic studies of allosteric,Na+-binding sites present in G protein coupled receptors are given together with data indicating the similarity between lithium and magnesium cations. In this context, similarities and dissimilarities between the useful “poison” with narrow therapeutic window (Li+) and the bivalent cation acting like cofactor of more than 300 enzymatic reactions (Mg2+) are pointed out together with results indicating enhanced activity of trimeric G proteins in bipolar disorder.

Content not available PDF Share



  1. Ahluwalia P, Grewaal DS, Singhal RL (1981) Brain gabaergic and dopaminergic systems following lithium treatment and withdrawal. Prog Neuropsychopharmacol 5: 527–530.
  2. Amihaesei IC (2014) Bipolar disorder, not so rare diagnosis: subtypes of different degrees of severity, diagnosis, therapy. Rev Med Chir Soc Med Nat Iasi 118: 111–115.
  3. Aprahamian I, Santos FS, dos Santos B, Talib L, Diniz BS, Radanovic M, Gattaz WF, Forlenza OV (2014) Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry 75: e672–e678.
  4. Aral H, Vecchio-Sadus A (2008) Toxicity of lithium to humans and the environment-a literature review. Ecotoxicol Environ Saf 70: 349–356.
  5. Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, Chen JJ, Mann JJ (2001) Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 25: 892–903.
  6. Avissar S, Murphy DL, Schreiber G (1991) Magnesium reversal of lithium inhibition of beta-adrenergic and muscarinic receptor coupling to G proteins. Biochem Pharmacol 41: 171–175.
  7. Avissar S, Schreiber G (2002) Toward molecular diagnostics of mood disorders in psychiatry. Trends Mol Med 8: 294–300.
  8. Avissar S, Schreiber G (2006) The involvement of G proteins and regulators of receptor-G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders. Clin Chim Acta 366: 37–47.
  9. Avissar S, Schreiber G, Danon A, Belmaker RH (1988) Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 331: 440–442.
  10. Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A (1970) Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 2: 326–330.
  11. Baastrup PC, Schou M (1967) Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 16: 162–172.
  12. Baldessarini RJ (2013) Mood-stabilizing agents. Chapter 3 in: Chemotherapy in Psychiatry: Pharmacologic Basis of Treatments for Major Mental Illness (3rd edition). Springer, New York, USA. p. 89–154.
  13. Banafshe HR, Mesdaghinia A, Arani MN, Ramezani MH, Heydari A, Hamidi GA (2012) Lithium attenuates pain-related behavior in a rat model of neuropathic pain: possible involvement of opioid system. Pharmacol Biochem Behav 100: 425–430.
  14. Bauer MS, Mitchner L (2004) What is a “mood stabilizer”? An evidence-based response. Am J Psychiatry 161: 3–18.
  15. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ (2004) Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 9: 386–392.
  16. Birch NJ (1994) Lithium ions have limited intracellular access: implication for cell regulation and pharmacology. J Trace Microprobe Techn 12: 1–16.Bird SJ, Maguire ME (1978) The agonist-specific effect of magnesium ion on binding by beta-adrenergic receptors in S49 lymphoma cells. Interaction of GTP and magnesium in adenylate cyclase activation. J Biol Chem 253: 8826–8834.
  17. Böckmann RA, Hac A, Heimburg T, Grubmuller H (2003) Effect of sodium chloride on a lipid bilayer. Biophys J 85: 1647–1655.
  18. Bone R, Frank L, Springer JP, Pollack SJ, Osborne SA, Atack JR, Knowles MR, McAllister G, Ragan CI, Broughton HB (1994) Structural analysis of inositol monophosphatase complexes with substrates. Biochemistry 33: 9460–9467.
  19. Bone R, Springer JP, Atack JR (1992) Structure of inositol monophosphatase, the putative target of lithium therapy. Proc Natl Acad Sci U S A 89: 10031–10035.
  20. Borras Blasco J, Murcia Lopez A, Romero Crespo I, Sirvent Pedreno A, Navarro Ruiz A (2005) Acute intoxication with sustained-release lithium carbonate tablets. A propos of a case. Farm Hosp 29: 140–143.
  21. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr., Chou JC, Keck PE Jr., Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57: 481–489
  22. Bowery NG, Hudson AL, Price GW (1987) GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 20: 365–383.
  23. Bowery NG, Price GW, Hudson AL, Hill DR, Wilkin GP, Turnbull MJ (1984) GABA receptor multiplicity. Visualization of different receptor types in the mammalian CNS. Neuropharmacology 23: 219–231.
  24. Brambilla P, Perez J, Barale F, Schettini G, Soares JC (2003) GABAergic dysfunction in mood disorders. Mol Psychiatry 8: 721–737, 715.
  25. Broemstrup T, Reuter N (2010) Molecular dynamics simulations of mixed acidic/zwitterionic phospholipid bilayers. Biophys J 99: 825–833.
  26. Brunello N, Tascedda F (2003) Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol 6: 181–189.
  27. Burns G, Herz A, Nikolarakis KE (1990) Stimulation of hypothalamic opioid peptide release by lithium is mediated by opioid autoreceptors: evidence from a combined in vitro, ex vivo study. Neuroscience 36: 691–697.
  28. Callado LF, Meana JJ, Grijalba B, Pazos A, Sastre M, Garcia-Sevilla JA (1998) Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem 70: 1114–1123.
  29. Can A, Schulze TG, Gould TD (2014) Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav 123: 3–16.
  30. Carroll BJ, Sharp PT (1971) Rubidium and lithium: opposite effects on amine-mediated excitement. Science 172: 1355–1357.
  31. Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29: 37–76.
  32. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V, Stevens RC (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330: 1091–1095.
  33. Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, Kanai H, Hough C, Hiroi T, Leeds P (2002) Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 4: 129–136.
  34. Cipriani A, Hawton K, Stockton S, Geddes JR (2013) Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346: f3646.
  35. Clarke RJ, Lupfert C (1999) Influence of anions and cations on the dipole potential of phosphatidylcholine vesicles: a basis for the Hofmeister effect. Biophys J 76: 2614–2624.
  36. Coleman DE, Berghuis AM, Lee E, Linder ME, Gilman AG, Sprang SR (1994a) Structures of active conformations of Gi alpha 1 and the mechanism of GTP hydrolysis. Science 265: 1405–1412.
  37. Coleman DE, Lee E, Mixon MB, Linder ME, Berghuis AM, Gilman AG, Sprang SR (1994b) Crystallization and preliminary crystallographic studies of Gi alpha 1 and mutants of Gi alpha 1 in the GTP and GDP-bound states. J Mol Biol 238: 630–634.
  38. Coleman DE, Sprang SR (1998) Crystal structures of the G protein Gi alpha 1 complexed with GDP and Mg2+: a crystallographic titration experiment. Biochemistry 37: 14376–14385.
  39. de Gandarias JM, Acebes I, Echevarria E, Vegas L, Abecia LC, Casis L (2000) Lithium alters mu-opioid receptor expression in the rat brain. Neurosci Lett 279: 9–12.
  40. Dehpour AR, Farsam H, Azizabadi-Farahani M (1995) Inhibition of the morphine withdrawal syndrome and the development of physical dependence by lithium in mice. Neuropharmacology 34: 115–121.
  41. Dehpour AR, Farsam H, Azizabadi-Farahani M (1994) The effect of lithium on morphine-induced analgesia in mice. Gen Pharmacol 25: 1635–1641.
  42. Deo AJ, Huang YY, Hodgkinson CA, Xin Y, Oquendo MA, Dwork AJ, Arango V, Brent DA, Goldman D, Mann JJ, Haghighi F (2013) A large-scale candidate gene analysis of mood disorders: evidence of neurotrophic tyrosine kinase receptor and opioid receptor signaling dysfunction. Psychiatr Genet 23: 47–55.
  43. Drevets WC (2001) Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11: 240–249.
  44. Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64: 327–337.
  45. Dupuis RE, Cooper AA, Rosamond LJ, Campbell-Bright S (1996) Multiple delayed peak lithium concentrations following acute intoxication with an extended-release product. Ann Pharmacother 30: 356–360.
  46. Ehrlich A, Schubert F, Pehrs C, Gallinat J (2015) Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder. Psychiatry Res 233: 73–80.
  47. Eisenberg M, Gresalfi T, Riccio T, McLaughlin S (1979) Adsorption of monovalent cations to bilayer membranes containing negative phospholipids. Biochemistry 18: 5213–5223.
  48. el-Mallakh RS (1983a) The Na,K-ATPase hypothesis for manic-depression. I. General considerations. Med Hypotheses 12: 253–268.
  49. el-Mallakh RS (1983b) The Na,K-ATPase hypothesis for manic-depression. II. The mechanism of action of lithium. Med Hypotheses 12: 269–282.
  50. el-Mallakh RS (2004) Ion homeostasis and the mechanism of action of lithium. Clin Neurosci Res 4: 227–231.
  51. el-Mallakh RS, Li R (1993) Is the Na(+)-K(+)-ATPase the link between phosphoinositide metabolism and bipolar disorder? J Neuropsychiatry Clin Neurosci 5: 361–368.
  52. el-Mallakh RS, Wyatt RJ (1995) The Na,K-ATPase hypothesis for bipolar illness. Biol Psychiatry 37: 235–244.
  53. Escriba PV, Ozaita A, Garcia-Sevilla JA (2004) Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology 29: 1512–1521.
  54. Fenalti G, Giguere PM, Katritch V, Huang XP, Thompson AA, Cherezov V, Roth BL, Stevens RC (2014) Molecular control of delta-opioid receptor signalling. Nature 506: 191–196.
  55. Filizola M, Devi LA (2012) Structural biology: How opioid drugs bind to receptors. Nature 485: 314–317.
  56. Fisar Z, Anders M, Tvrzicka E, Stankova B (2005) Effect of long-term administration of antidepressants on the lipid composition of brain plasma membranes. Gen Physiol Biophys 24: 221–236.
  57. Freland L, Beaulieu JM (2012) Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 5: article 14.
  58. Friedman E, Wang HY (1996) Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. J Neurochem 67: 1145–1152.
  59. Gabilondo AM, Meana JJ, Garcia-Sevilla JA (1995) Increased density of mu‑opioid receptors in the postmortem brain of suicide victims. Brain Res 682: 245–250.
  60. Garcia-Celma JJ, Hatahet L, Kunz W, Fendler K (2007) Specific anion and cation binding to lipid membranes investigated on a solid supported membrane. Langmuir 23: 10074–10080.
  61. General discussion (2013) Ion specific hofmeister effects. Faraday Discussions 160: 311–327.
  62. Gershon S, Chengappa KN, Malhi GS (2009) Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 11: 34–44.
  63. Ghasemi M, Dehpour AR (2011) The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends Pharmacol Sci 32: 420–434.
  64. Gierschik P, Moghtader R, Straub C, Dieterich K, Jakobs KH (1991) Signal amplification in HL-60 granulocytes. Evidence that the chemotactic peptide receptor catalytically activates guanine-nucleotide-binding regulatory proteins in native plasma membranes. Eur J Biochem 197: 725–732.
  65. Gierschik P, Steisslinger M, Sidiropoulos D, Herrmann E, Jakobs KH (1989) Dual Mg2+ control of formyl-peptide-receptor--G-protein interaction in HL 60 cells. Evidence that the low-agonist-affinity receptor interacts with and activates the G-protein. Eur J Biochem 183: 97–105.
  66. Gill R, Mohammed F, Badyal R, Coates L, Erskine P, Thompson D, Cooper J, Gore M, Wood S (2005) High-resolution structure of myo-inositol monophosphatase, the putative target of lithium therapy. Acta Crystallogr D Biol Crystallogr 61: 545–555.
  67. Gill J, Singh H, Nugent K (2003) Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy 23: 811–815.
  68. Gilman AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56: 615–649.
  69. Glossmann H, Presek P (1979) Alpha noradrenergic receptors in brain membranes: sodium, magnesium and guanyl nucleotides modulate agonist binding. Naunyn Schmiedebergs Arch Pharmacol 306: 67–73.
  70. Gonzalez-Maeso J, Meana JJ (2006) Heterotrimeric g proteins: insights into the neurobiology of mood disorders. Curr Neuropharmacol 4: 127–138.
  71. Gonzalez-Maeso J, Rodriguez-Puertas R, Meana JJ, Garcia-Sevilla JA, Guimon J (2002) Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors. Mol Psychiatry 7: 755–767.
  72. Grandjean EM, Aubry JM (2009a) Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder. CNS Drugs 23: 225–240.
  73. Grandjean EM, Aubry JM (2009b) Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs 23: 331–349.
  74. Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, Weis WI, Kobilka BK (2012) Structure of the delta-opioid receptor bound to naltrindole. Nature 485: 400–404.
  75. Gray JD, McEwen BS (2013) Lithium’s role in neural plasticity and its implications for mood disorders. Acta Psychiatr Scand 128: 347–361.
  76. Gross-Isseroff R, Biegon A, Voet H, Weizman A (1998) The suicide brain: a review of postmortem receptor/transporter binding studies. Neurosci Biobehav Rev 22: 653–661.
  77. Gross-Isseroff R, Dillon KA, Israeli M, Biegon A (1990) Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res 530: 312–316.
  78. Hammond WA (1871) A treatise on diseases of the nervous system. Section 1: Diseases of the brain, Chapter XV: Insanity. D. Appleton and Company, New York, USA. p. 324–384.
  79. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM (2002) Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80: 589–597.
  80. Hauser H, Shipley GG (1981) Crystallization of phosphatidylserine bilayers induced by lithium. J Biol Chem 256: 11377–11380.
  81. Hauser H, Shipley GG (1983) Interactions of monovalent cations with phosphatidylserine bilayer membranes. Biochemistry 22: 2171–2178.
  82. Higashijima T, Ferguson KM, Smigel MD, Gilman AG (1987a) The effect of GTP and Mg2+ on the GTPase activity and the fluorescent properties of Go. J Biol Chem 262: 757–761.
  83. Higashijima T, Ferguson KM, Sternweis PC, Ross EM, Smigel MD, Gilman AG (1987b) The effect of activating ligands on the intrinsic fluorescence of guanine nucleotide-binding regulatory proteins. J Biol Chem 262: 752–756.
  84. Higashijima T, Ferguson KM, Sternweis PC, Smigel MD, Gilman AG (1987c) Effects of Mg2+ and the beta gamma-subunit complex on the interactions of guanine nucleotides with G proteins. J Biol Chem 262: 762–766.
  85. Hilf G, Gierschik P, Jakobs KH (1989) Muscarinic acetylcholine receptor-stimulated binding of guanosine 5’-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes. Eur J Biochem 186: 725–731.
  86. Hofmeister F (1888) Zur Lehre von der Wirkung der Salze. Arch Exp Pathol Pharmacol 24: 247–260.
  87. Hokin LE, Dixon JF, Los GV (1996) A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices. Adv Enzyme Regul 36: 229–244.
  88. Honar H, Riazi K, Homayoun H, Demehri S, Dehghani M, Vafaie K, Ebrahimkhani MR, Rashidi N, Gaskari SA, Dehpour AR (2004) Lithium inhibits the modulatory effects of morphine on susceptibility to pentylenetetrazole-induced clonic seizure in mice: involvement of a nitric oxide pathway. Brain Res 1029: 48–55.
  89. Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, Ardau R, Arias B, Backlund L, Banzato CE, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Brichant-Petitjean C, Bui ET, Cervantes P, Chen GB, Chen HC, Chillotti C, Cichon S, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dantas CR, Dayer A, Étain B, Falkai P, Forstner AJ, Frisén L, Fullerton JM, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Jaramillo CA, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Erkelenz D, Rouleau GA, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm T, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt S, Wright A, Young LT, Zandi PP, Potash JB, DePaulo JR, Bauer M, Reininghaus EZ, Novák T, Aubry JM, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo PH, Kato T, Grigoroiu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray NR, Kelsoe JR, Alda M, Rietschel M, McMahon FJ, Schulze TG (2016) Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet pii: S0140-S6736(16)00143-4, doi: 10.1016/S0140-6736(16)00143-4.
  90. Hsiung SC, Adlersberg M, Arango V, Mann JJ, Tamir H, Liu KP (2003) Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. J Neurochem 87: 182–194.
  91. Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB, Mann JJ, Arango V (2004) Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 9: 184–190.
  92. Jaeger A, Sauder P, Kopferschmitt J, Tritsch L, Flesch F (1993) When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. J Toxicol Clin Toxicol 31: 429–447.
  93. Jahnen-Dechent W, Ketteler M (2012) Magnesium basics. Clin Kidney J 5: i3–i14.
  94. Jope RS, Williams MB (1994) Lithium and brain signal transduction systems. Biochem Pharmacol 47: 429–441.
  95. Jurkiewicz P, Cwiklik L, Jungwirth P, Hof M (2011) Lipid hydration and mobility: an interplay between fluorescence solvent relaxation experiments and molecular dynamics simulations. Biochimie 94: 26–32.
  96. Jurkiewicz P, Cwiklik L, Vojtiskova A, Jungwirth P, Hof M (2012) Structure, dynamics, and hydration of POPC/POPS bilayers suspended in NaCl, KCl, and CsCl solutions. Biochim Biophys Acta 1818: 609–616.
  97. Jutkiewicz EM (2006) The antidepressant -like effects of delta-opioid receptor agonists. Mol Interv 6: 162–169.
  98. Kato T (2008) Molecular neurobiology of bipolar disorder: a disease of “mood-stabilizing neurons”? Trends Neurosci 31: 495–503.
  99. Katritch V, Fenalti G, Abola E., Roth BL, Cherezov V, Stevens RC (2014) Allosteric sodium in class A GPCR signaling. Trends Biochem Sci 39: 233–244.
  100. Keltner NU, Steele D (2015) Psychiatric Nursing. Chapter 16: Antimanic drugs. Elsevier Mosby, St. Louis, USA. p. 172–181.
  101. Kleemann P, Papa D, Vigil-Cruz S, Seifert R (2008) Functional reconstitution of the human chemokine receptor CXCR4 with G(i)/G (o)-proteins in Sf9 insect cells. Naunyn Schmiedebergs Arch Pharmacol 378: 261–274.
  102. Koltsova SV, Trushina YA, Akimova OA, Hamet P, Orlov SN (2011) Molecular origin of Na(+)/Li(+) exchanger: Evidence against the involvement of major cloned erythrocyte transporters. Pathophysiology 18: 207–213.
  103. Komoroski RA, Lindquist DM, Pearce JM (2013) Lithium compartmentation in brain by 7Li MRS: effect of total lithium concentration. NMR Biomed 26: 1152–1157.
  104. Komoroski RA, Pearce JM (2008) Estimating intracellular lithium in brain in vivo by localized 7Li magnetic resonance spectroscopy. Magn Reson Med 60: 21–26.
  105. Kong H, Raynor K, Yasuda K, Moe ST, Portoghese PS, Bell GI, Reisine T (1993) A single residue, aspartic acid 95, in the delta opioid receptor specifies selective high affinity agonist binding. J Biol Chem 268: 23055–23058.
  106. Kovacsics CE, Gottesman II, Gould TD (2009) Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 49: 175–198.
  107. Kugaya A, Sanacora G (2005) Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 10: 808–819.
  108. Kunz W, Lo Nostro P, Ninham BW (2004) The present state of affairs with Hofmeister effects. Curr Opin Colloid Interface Sci 9: 1–18.
  109. Kurumaji A, Mitsushio H, Takashima M (1988) Chronic dietary treatment with antidepressants decrease brain Met-enkephalin-like immunoreactivity in the rat. Psychopharmacology (Berl) 94: 188–192.
  110. Lefkowitz R., Cotecchia S, Samama P, Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14: 303–307
  111. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, Han GW, Roth CB, Heitman LH, Ijzerman AP, Cherezov V, Stevens RC (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337: 232–236.
  112. Lopez Cascales JJ, Garcia de la Torre J (1997) Effect of lithium and sodium ions on a charged membrane of dipalmitoylphosphatidylserine: a study by molecular dynamics simulation. Biochim Biophys Acta 1330: 145–156.
  113. Lopez-Corcuera B, Gimenez C, Aragon C (1988) Change of synaptic membrane lipid composition and fluidity by chronic administration of lithium. Biochim Biophys Acta 939: 467–475.
  114. López-Jaramillo C, Lopera-Vásquez J, Ospina-Duque J, García J, Gallo A, Cortez V, Palacio C, Torrent C, Martínez-Arán A, Vieta E (2010) Lithium treatment effects on the neuropsychological functioning of patients with bipolar I disorder. J Clin Psychiatry 71: 1055–1060.
  115. Mahler J, Persson I (2012) A study of the hydration of the alkali metal ions in aqueous solution. Inorg Chem 51: 425–438.
  116. Malarkey CS, Wang G, Ballicora MA, Mota de Freitas DE (2008) Evidence for two distinct Mg2+ binding sites in G(s alpha) and G(i alpha1) proteins. Biochem Biophys Res Commun 372: 866–869.
  117. Malhi GS, Tanious M, Das P, Coulston CM, Berk M (2013) Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 27: 135–153.
  118. Mallinger AG, Frank E, Thase ME, Dippold CS, Kupfer DJ (1997) Low rate of membrane lithium transport during treatment correlates with outcome of maintenance pharmacotherapy in bipolar disorder. Neuropsychopharmacology 16: 325–332.
  119. Mallinger AG, Himmelhoch JM, Thase ME, Dippold C, Knopf S (1990) Reduced cell membrane affinity for lithium ion during maintenance treatment of bipolar affective disorder. Biol Psychiatry 27: 795–798.
  120. Manchia M, Adli M, Akula N, Ardau R, Aubry JM, Backlund L, Banzato CE, Baune BT, Bellivier F, Bengesser S, Biernacka JM, Brichant-Petitjean C, Bui E, Calkin C, Cheng AT, Chillotti C, Cichon S, Clark S, Czerski PM, Dantas C, Zompo MD, Depaulo JR, Detera-Wadleigh SD, Etain B, Falkai P, Frisen L, Frye MA, Fullerton J, Gard S, Garnham J, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hoban R, Hou L, Jamain S, Kahn JP, Kassem L, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwicki S, Kuo PH, Kusumi I, Laje G, Lavebratt C, Leboyer M, Leckband SG, Lopez Jaramillo CA, Maj M, Malafosse A, Martinsson L, Masui T, Mitchell PB, Mondimore F, Monteleone P, Nallet A, Neuner M, Novak T, O’Donovan C, Osby U, Ozaki N, Perlis RH, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reininghaus E, Richardson S, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert OK, Schweizer B, Seemuller F, Grigoroiu-Serbanescu M, Severino G, Seymour LR, Slaney C, Smoller JW, Squassina A, Stamm T, Steele J, Stopkova P, Tighe SK, Tortorella A, Turecki G, Wray NR, Wright A, Zandi PP, Zilles D, Bauer M, Rietschel M, McMahon FJ, Schulze TG, Alda M (2013) Assessment of response to lithium maintenance treatment in bipolar disorder: a consortium on lithium genetics (ConLiGen) report. PLoS One 8: e65636.
  121. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, Pardo L, Weis WI, Kobilka BK, Granier S (2012) Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485: 321–326.
  122. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A (2003) The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 60: 497–502.
  123. McLaughlin A, Grathwohl C, McLaughlin S (1978) The adsorption of divalent cations to phosphatidylcholine bilayer membranes. Biochim Biophys Acta 513: 338–357.
  124. Miller-Gallacher JL, Nehme R, Warne T, Edwards PC, Schertler GF, Leslie AG, Tate CG (2014) The 2.1 A resolution structure of cyanopindolol-bound beta1-adrenoceptor identifies an intramembrane Na+ ion that stabilises the ligand-free receptor. PLoS One 9: e92727.
  125. Minadeo N, Layden B, Amari LV, Thomas V, Radloff K, Srinivasan C, Hamm HE, de Freitas DM (2001) Effect of Li+ upon the Mg2+-dependent activation of recombinant Gialpha1. Arch Biochem Biophys 388: 7–12.
  126. Mitchell PB, Hadzi-Pavlovic D (2000) Lithium treatment for bipolar disorder. Bull World Health Organ 78: 515–517.
  127. Mork A, Geisler A (1989) Effects of lithium ex vivo on the GTP-mediated inhibition of calcium-stimulated adenylate cyclase activity in rat brain. Eur J Pharmacol 168: 347–354.
  128. Mota de Freitas D, Castro MM, Geraldes CF (2006) Is competition between Li+ and Mg2+ the underlying theme in the proposed mechanisms for the pharmacological action of lithium salts in bipolar disorder? Acc Chem Res 39: 283–291.
  129. Muller CP, Reichel M, Muhle C, Rhein C, Gulbins E, Kornhuber J (2015) Brain membrane lipids in major depression and anxiety disorders. Biochim Biophys Acta 1851: 1052–1065.
  130. Murru A, Popovic D, Pacchiarotti I, Hidalgo D, León-Caballero J, Vieta E (2015) Management of adverse effects of mood stabilizers. Curr Psychiatry Rep 17: 603.
  131. Newman ME, Drummer D, Lerer B (1990) Single and combined effects of desimipramine and lithium on serotonergic receptor number and second messenger function in rat brain. J Pharmacol Exp Ther 252: 826–831.
  132. Ng WX, Lau IY, Graham S, Sim K (2009) Neurobiological evidence for thalamic, hippocampal and related glutamatergic abnormalities in bipolar disorder: a review and synthesis. Neurosci Biobehav Rev 33: 336–354.
  133. Nicely NI, Dennison SM, Spicer L, Scearce RM, Kelsoe G, Ueda Y, Chen H, Liao HX, Alam SM, Haynes BF (2004) Crystal structure of a non‑neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nat Struct Mol Biol 17: 1492–1494.
  134. Nonaka S, Hough CJ, Chuang DM (1998) Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 95: 2642–2647.
  135. Odagaki Y, Nishi N, Koyama T (1997) Lack of interfering effects of lithium on receptor/G protein coupling in human platelet and rat brain membranes. Biol Psychiatry 42: 697–703.
  136. Orrego F, Villanueva S (1993) The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience 56: 539–555.
  137. Oruch R, Elderbi MA, Khattab H., Pryme IF, Lund A (2014) Lithium: A review of pharmacology, clinical uses, and toxicity. Eur J Pharmacol 740: 646–673.
  138. Pabst G, Hodzic A, Strancar J, Danner S, Rappolt M, Laggner P (2007) Rigidification of neutral lipid bilayers in the presence of salts. Biophys J 93: 2688–2696.
  139. Padgett CL, Slesinger PA (2010) GABAB receptor coupling to G-proteins and ion channels. Adv Pharmacol 58: 123–147.
  140. Pandit SA, Bostick D, Berkowitz ML (2003) Mixed bilayer containing dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylserine: lipid complexation, ion binding, and electrostatics. Biophys J 85: 3120–3131.
  141. Parsons DF, Bostrom M, Maceina TJ, Salis A, Ninham BW (2010) Why direct or reversed Hofmeister series? Interplay of hydration, non-electrostatic potentials, and ion size. Langmuir 26: 3323–3328.
  142. Pasternak GW, Snowman AM, Snyder SH (1975) Selective enhancement of [3H]opiate agonist binding by divalent cations. Mol Pharmacol 11: 735–744.
  143. Pasternak GW, Snyder SH (1975) Identification of novel high affinity opiate receptor binding in rat brain. Nature 253: 563–565.
  144. Paterson SJ, Robson LE, Kosterlitz HW (1986) Control by cations of opioid binding in guinea pig brain membranes. Proc Natl Acad Sci U S A 83: 6216–6220.
  145. Peces R, Pobes A (2001) Effectiveness of haemodialysis with high-flux membranes in the extracorporeal therapy of life-threatening acute lithium intoxication. Nephrol Dial Transplant 16: 1301–1303.
  146. Pert CB, Snyder SH (1974) Opiate receptor binding of agonists and antagonists affected differentially by sodium. Mol Pharmacol 10: 868–879.
  147. Pert C, Pasternak G, Snyder SH (1973) Opiate agonists and antagonists discriminated by receptor binding in brain. Science 182: 1359–1361.
  148. Phillips ML, Kupfer DJ (2013) Bipolar disorder diagnosis: challenges and future directions. Lancet 381: 1663–1671.
  149. Pinard A, Seddik R, Bettler B (2010) GABAB receptors: physiological functions and mechanisms of diversity. Adv Pharmacol 58: 231–255.
  150. Porasso RD, Lopez Cascales JJ (2009) Study of the effect of Na+ and Ca2+ ion concentration on the structure of an asymmetric DPPC/DPPC + DPPS lipid bilayer by molecular dynamics simulation. Colloids Surf B Biointerfaces 73: 42–50.
  151. Rajkowska G (2002) Cell pathology in bipolar disorder. Bipolar Disord 4: 105–116.
  152. Rajkowska G, Halaris A, Selemon LD (2001) Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 49: 741–752.
  153. Rapoport SI, Basselin M, Kim HW, Rao JS (2009) Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 61: 185–209.
  154. Regehr WG, Carey MR, Best AR (2009) Activity-dependent regulation of synapses by retrograde messengers. Neuron 63: 154–170.
  155. Reiser G, Duhm J (1982) Transport pathways for lithium ions in neuroblastoma x glioma hybrid cells at “therapeutic” concentrations of Li+. Brain Res 252: 247–258.
  156. Rihmer Z, Kiss K (2002) Bipolar disorders and suicidal behaviour. Bipolar Disord 4: 21–25.
  157. Rybakowski JK (2013) Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs 27: 165–173.
  158. Rybakowski J, Drogowska J, Abramowicz M, Chłopocka-Woźniak M, Czekalski S (2012) The effect of long-term lithium treatment on kidney function. Psychiatr Pol 46: 627–636.
  159. Sakaba T, Neher E (2003) Direct modulation of synaptic vesicle priming by GABA(B) receptor activation at a glutamatergic synapse. Nature 424: 775–778.
  160. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7: 426–437.
  161. Sands JM, Bichet DG, Physicians ACo, Society AP (2006) Nephrogenic diabetes insipidus. Ann Intern Med 144: 186–194.
  162. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ (2000) Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174–180.
  163. Scarr E, Money TT, Pavey G, Neo J, Dean B (2012) Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study. BMC Psychiatry 12: 126.
  164. Schloesser RJ, Martinowich K, Manji HK (2012) Mood-stabilizing drugs: mechanisms of action. Trends Neurosci 35: 36–46.
  165. Schnell D, Seifert R (2010) Modulation of histamine H(3) receptor function by monovalent ions. Neurosci Lett 472: 114–118.
  166. Schou M (1999) Perspectives on lithium treatment of bipolar disorder: action, efficacy, effect on suicidal behavior. Bipolar Disord 1: 5–10.
  167. Schou M, Juel-Nielsen N, Stromgren E, Voldby H (1954) The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 17: 250–260.
  168. Schreiber G, Avissar S (1991) Lithium sensitive G protein hyperfunction: a dynamic model for the pathogenesis of bipolar affective disorder. Med Hypotheses 35: 237–243.
  169. Schreiber G, Avissar S (2007) Regulators of G-protein-coupled receptor-G-protein coupling: antidepressants mechanism of action. Expert Rev Neurother 7: 75–84.
  170. Schreiber G, Avissar S, Danon A, Belmaker RH (1991) Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. Biol Psychiatry 29: 273–280.
  171. Schwierz N, Horinek D, Netz RR (2010) Reversed anionic Hofmeister series: the interplay of surface charge and surface polarity. Langmuir 26: 7370–7379.
  172. Seifert R (2001) Monovalent anions differentially modulate coupling of the beta2-adrenoceptor to G(s)alpha splice variants. J Pharmacol Exp Ther 298: 840–847.
  173. Seifert R, Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366: 381–416.
  174. Seifert R, Wenzel-Seifert K (2001) Unmasking different constitutive activity of four chemoattractant receptors using Na+ as universal stabilizer of the inactive (R) state. Receptors Channels 7: 357–369.
  175. Selent J, Sanz F, Pastor M, De Fabritiis G (2010) Induced effects of sodium ions on dopaminergic G-protein coupled receptors. PLoS Comput Biol 6: e1000884.
  176. Sequeira A, Mamdani F, Lalovic A, Anguelova M, Lesage A, Seguin M, Chawky N, Desautels A, Turecki G (2004) Alpha 2A adrenergic receptor gene and suicide. Psychiatry Res 125: 87–93.
  177. Shang Y, LeRouzic V, Schneider S, Bisignano P, Pasternak GW, Filizola M (2014) Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions. Biochemistry 53: 5140–5149.
  178. Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, Abagyan R, Cherezov V, Liu W, Han GW, Kobayashi T, Stevens RC, Iwata S (2011) Structure of the human histamine H1 receptor complex with doxepin. Nature 475: 65–70.
  179. Shine B, McKnight RF, Leaver L, Geddes JR (2015) Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 386: 461–468.
  180. Sibley DR, Creese I (1983) Regulation of ligand binding to pituitary D-2 dopaminergic receptors. Effects of divalent cations and functional group modification. J Biol Chem 258: 4957–4965.
  181. Singh T, Rajput M (2006) Misdiagnosis of bipolar disorder. Psychiatry (Edgmont) 3: 57–63.
  182. Soares JC, Boada F, Keshavan MS (2000) Brain lithium measurements with (7)Li magnetic resonance spectroscopy (MRS): a literature review. Eur Neuropsychopharmacol 10: 151–158.
  183. Srinivasan C, Toon J, Amari L, Abukhdeir AM, Hamm H, Geraldes CF, Ho YK, Mota de Freitas D (2004) Competition between lithium and magnesium ions for the G-protein transducin in the guanosine 5’-diphosphate bound conformation. J Inorg Biochem 98: 691–701.
  184. Strasser A, Wittmann HJ, Schneider EH, Seifert R (2015) Modulation of GPCRs by monovalent cations and anions. Naunyn Schmiedebergs Arch Pharmacol 388: 363–380.
  185. Sunahara RK, Tesmer JJ, Gilman AG, Sprang SR (1997) Crystal structure of the adenylyl cyclase activator Gsalpha. Science 278: 1943–1947.
  186. Suwalsky M, Fierro P, Villena F, Sotomayor CP (2007) Effects of lithium on the human erythrocyte membrane and molecular models. Biophys Chem 129: 36–42.
  187. Tatulian SA (1987) Binding of alkaline-earth metal cations and some anions to phosphatidylcholine liposomes. Eur J Biochem 170: 413–420.
  188. Teixeira NA, Pereira DG, Hermini AH (1995) Lithium treatment prolongs shock-induced hypoalgesia. Braz J Med Biol Res 28: 791–799.
  189. Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR (1997) Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. Science 278: 1907–1916.
  190. Thellier ME, Wissocq J-C, Ripoll C (1997) NCR and SIMS study of whether lithium ions have limited intracellular access. Journal of Trace and Microprobe Techniques 15: 93–99.
  191. Tsai BS, Lefkowitz RJ (1978) Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets. Mol Pharmacol 14: 540–548.
  192. Tsai BS, Lefkowitz RJ (1979) Agonist-specific effects of guanine nucleotides on alpha-adrenergic receptors in human platelets. Mol Pharmacol 16: 61–68.
  193. Ullrich A, Baierl P, ten Bruggencate G (1980) Extracellular potassium in rat cerebellar cortex during acute and chronic lithium application. Brain Res 192: 287–290.
  194. Ullrich A, Steinberg R, Baierl P, ten Bruggencate G (1982) Changes in extracellular potassium and calcium in rat cerebellar cortex related to local inhibition of the sodium pump. Pflugers Arch 395: 108–114.
  195. Uwai Y, Arima R, Takatsu C, Furuta R, Kawasaki T, Nabekura T (2014) Sodium-phosphate cotransporter mediates reabsorption of lithium in rat kidney. Pharmacol Res 87: 94–98.
  196. Vaccaro O, Cuomo V, Trevisan M, Cirillo M, Panarelli W, Laurenzi M, Mancini M, Riccardi G (2005) Enhanced Na-Li countertransport: a marker of inherited susceptibility to type 2 diabetes. Int J Epidemiol 34: 1123–1128.
  197. Vacha R, Siu SW, Petrov M, Böckmann RA, Barucha-Kraszewska J, Jurkiewicz P, Hof M, Berkowitz ML, Jungwirth P (2009) Effects of alkali cations and halide anions on the DOPC lipid membrane. J Phys Chem A 113: 7235–7243.
  198. Vargas C, Tannhauser M, Barros HM (1998) Dissimilar effects of lithium and valproic acid on GABA and glutamine concentrations in rat cerebrospinal fluid. Gen Pharmacol 30: 601–604.
  199. Vazquez GH, Tondo L, Undurraga J, Baldessarini RJ (2013) Overview of antidepressant treatment of bipolar depression. Int J Neuropsychopharmacol 16, 1673–1685.
  200. Vosahlikova M, Jurkiewicz P, Roubalova L, Hof M, Svoboda P (2014) High- and low-affinity sites for sodium in delta-OR-Gi1alpha (Cys (351)-Ile (351)) fusion protein stably expressed in HEK293 cells; functional significance and correlation with biophysical state of plasma membrane. Naunyn Schmiedebergs Arch Pharmacol 387: 487–502.
  201. Wang HY, Friedman E (1999) Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes. Neuropharmacology 38: 403–414.
  202. Webb AL, Solomon DA, Ryan CE (2001) Lithium levels and toxicity among hospitalized patients. Psychiatr Serv 52: 229–231.
  203. Wei JW, Sulakhe PV (1980) Cardiac muscarinic cholinergic receptor sites: opposing regulation by divalent cations and guanine nucleotides of receptor-agonist interaction. Eur J Pharmacol 62: 345–347.
  204. Werling LL, Brown SR, Puttfarcken P, Cox BM (1986) Sodium regulation of agonist binding at opioid receptors. II. Effects of sodium replacement on opioid binding in guinea pig cortical membranes. Mol Pharmacol 30: 90–95.
  205. Williams LT, Mullikin D, Lefkowitz RJ (1978) Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors. J Biol Chem 253: 2984–2989.
  206. Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296: 678–682.
  207. Wittmann HJ, Seifert R, Strasser A (2014) Sodium binding to hH3R and hH 4R--a molecular modeling study. J Mol Model 20: 2394.
  208. Young LT, Li PP, Kish SJ, Siu KP, Warsh JJ (1991) Postmortem cerebral cortex Gs alpha-subunit levels are elevated in bipolar affective disorder. Brain Res 553: 323–326.
  209. Young W (2009) Review of lithium effects on brain and blood. Cell Transplant 18: 951–975.
  210. Yuan S, Vogel H, Filipek S (2013) The role of water and sodium ions in the activation of the mu-opioid receptor. Angew Chem Int Ed Engl 52: 10112–10115.
  211. Zarate CA Jr., Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, Charney DS, Manji HK (2003) Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 1003: 273–291.
  212. Zarate CA, Quiroz J, Payne J, Manji HK (2002) Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 36: 35–83.